STAT+：诺华Lp(a)药物研发失败引发对心血管策略的质疑
摘要
芝加哥——脂蛋白(a)是一种影响五分之一人群的心血管疾病遗传风险因素，正成为旨在减少高危人群心脏病发作、卒中和死亡的新型疗法的靶点。今年早些时候，针对该颗粒日益增多的研究领域遭受打击，当时的主要结果显示，一种实验性药物降低了Lp(a)，但未能减少严重结局。周六，在美国心脏协会科学会议上公布了这项由诺华资助的研究的更多细节，并同时发表在《新英格兰医学杂志》上。在3期试验中，药物pelacarsen大幅降低了Lp(a)——一种脂质和蛋白质的混合物，高水平时可增加严重心脏问题的风险。但尽管Lp(a)降低，HORIZON试验
English
CHICAGO — Lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, is the target of novel therapies trying to cut down heart attacks, strokes, and deaths in those at risk. The growing field of research aimed at the particle took a hit earlier this year when top-line results showed an experimental drug reduced Lp(a) but failed to lower serious outcomes. More details of the study, funded by Novartis, were revealed Saturday at the American Heart Association’s scientific sessions and published simultaneously in the New England Journal of Medicine . In the Phase 3 trial, the drug pelacarsen dramatically lowered Lp(a), a mashup of lipids and proteins that at high levels can heighten the risk of severe heart problems. But despite lower Lp(a), the HORIZON trial sh